ZNTL — Zentalis Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-04-03.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ZNTL
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
| 2026-06-30 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-03 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-05-22 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-19 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-04-09 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-14 | WALTERS SUSAN BERKLEY 10% owner | Open-market purchase | 4.3M | 3.50 | 15.2M |
| 2026-08-14 | WALTERS WILLIAM THURMAN 10% owner | Open-market purchase | 4.3M | 3.50 | 15.2M |
| 2026-08-14 | WALTERS GROUP 10% owner | Open-market purchase | 4.3M | 3.50 | 15.2M |
| 2026-06-16 | Myers Scott Dunseth Director | Grant or award | 57.1K | 0.00 | 0 |
| 2026-06-16 | Johnson David Michael Director | Grant or award | 57.1K | 0.00 | 0 |
| 2026-06-16 | Skvarka Jan Director | Grant or award | 57.1K | 0.00 | 0 |
| 2026-06-16 | Walker Luke Nathaniel Director | Grant or award | 57.1K | 0.00 | 0 |
| 2026-06-16 | Kariuki Enoch Director | Grant or award | 57.1K | 0.00 | 0 |
| 2026-05-26 | Campbell Shannon Director | Grant or award | 114.2K | 0.00 | 0 |
| 2026-02-10 | Vultaggio Vincent PAO and PFO | Open-market sale 10b5-1 plan | 6.9K | 2.42 | 16.7K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| 5AM Venture Management, LLC | 9.2M | 3.9M |
| Squadron Capital Management LLC | 8.5M | 3.6M |
| TWO SIGMA INVESTMENTS, LP | 6.9M | 3.0M |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.4M | 2.3M |
| RENAISSANCE TECHNOLOGIES LLC | 4.5M | 1.9M |
| CITADEL ADVISORS LLC | 4.1M | 1.7M |
| D. E. Shaw & Co., Inc. | 3.5M | 1.5M |
| Opaleye Management Inc. | 3.3M | 1.4M |
| Decheng Capital LLC | 3.1M | 1.3M |
| MILLENNIUM MANAGEMENT LLC | 3.0M | 1.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Zentalis Pharmaceuticals, Inc. (ZNTL) filed form 8-K · 2026-08-14 · SEC EDGAR
- Why is Zentalis Pharmaceuticals stock tumbling today? · 2026-08-14
- Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share · 2026-08-14
- Zentalis Pharmaceuticals stock falls on public offering news · 2026-08-13
Ask the AI about ZNTL
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →